On January 25, 2016, the Board of Directors of EyeGate Pharmaceuticals, Inc. upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Paul Chaney, an independent member and Chairman of the Board, as a member of the Audit Committee of the Board. In connection with Mr. Chaney's appointment to the Audit Committee, Thomas Balland resigned from his position as a member of the Audit Committee. Mr. Balland remains an independent member of the Board.

Mr. Balland's decision to resign as a member of the Audit Committee did not involve any disagreement with the company, its management or the Board.